On September 2, Regeneron Pharmaceuticals rose 3.01% in regular trading, trading at $822.97/share, with turnover of $303 million. The move came after RBC Capital Markets published a report indicating that Regeneron may be considering a significant expansion of its long-standing drug partnership with Sanofi.
According to the RBC report, the current collaboration covers only Dupixent and Kevzara, but both companies have expressed openness to renegotiating the agreement. RBC noted that the partnership could be broadened to include several new immunology medicines, and that Regeneron may seek a more balanced global profit-sharing arrangement. Under the existing structure, Sanofi funds most development costs upfront while Regeneron reimburses those expenses over time. RBC maintained its sector-perform rating on Regeneron stock, cautioning that any financial benefits from a restructured deal would likely take time to materialize.
Separately, the company has a key regulatory catalyst ahead, with the FDA granting priority review to Cemdisiran for generalized myasthenia gravis, with a target action date in November. If approved, it would be the first siRNA therapy for the condition.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments